Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 5, 2001

View Archived Issues

Nexell awarded orphan drug status for stem cell product

Valentis acquires electroporation technology license from Genetronics

Abgenix licenses novel cancer target for development of potential antibody therapies

Elan highlights oncology portfolio

Encouraging results from phase I study of inhalable leuprolide

Alista associated with positive results in female sexual dysfunction

Affitech and Axaron form strategic alliance for genomics-based antibody drugs

Praecis proceeds with clinical plans for Plenaxis following discussions with the FDA

Research snapshots in neuroprotection

Second approval for first oral drug for the treatment of PAH

Cephalon announces agreement to acquire French pharmaceutical company

Regulatory update on Glivec/Gleevec

Further characterization of the bronchodilating effects of Ro-25-1553 in human preparations

Expression of mda-7 gene downregulated in advanced human melanomas; INGN-241 blocks growth

VNS effective and safe in chronic or recurrent treatment-resistant depression

PH-50: a promising new vascular imaging agent from Photogen

Long-term pegvisomant beneficial in acromegaly

Fusion proteins useful for DC-based immunotherapy of tumors

Delivery of polynucleotides into cells using histones under study at Biogeny

Sankyo discloses new triazole antifungal agents in recent patent

New broad-spectrum antibacterial agents in the GSK pipeline

Antiinflammatory and analgesic effects demonstrated for new PLA2 inhibitors

Cyclooxygenase inhibitors synthesized at Takeda useful for inflammation, pain and fever

Recent patent covers oxytocin receptor ligands identified at Sanofi-Synthelabo

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 18, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 18, 2025.
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
Maintenance, man: Lilly’s phase III weight trial hits goals
BioWorld
Eli Lilly and Co. took another step toward adding a way for patients to hang onto their weight loss when the firm disclosed positive top-line data from the phase...
AI drug developer Insilico to raise $292 million in Hong Kong IPO
BioWorld
Insilico Medicine Inc. plans to raise HK$2.27 billion (US$292 million) in its IPO on the Hong Kong Securities Exchange to advance its clinical pipeline and invest...